BioCryst to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
BioCryst Pharma (BCRX) PT Raised to $18 at Cowen
May 6, 2021 10:19 AM EDTCowen analyst Ken Cacciatore raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $18.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "BioCryst reported strong first full quarter Orladeyo sales, and we view the initial launch metrics of meaningful patient switches (vs. clinical trial... More
